A̅repa, a New Zealand-based supplement company, is driving innovation in mood and cognition enhancement with a newly patented molecule, sarmentosin, extracted from locally grown blackcurrants. This little-known glycoside, now trademarked as Neuroberry, shows promising potential to inhibit enzymes that degrade “happy hormones” like serotonin, dopamine, and norepinephrine. According to A̅repa co-founder Angus Brown, this breakthrough may have a similar impact on the food and supplement industries as the discovery of caffeine, potentially enhancing mood, motivation, and cognitive function without caffeine’s side effects.
The company has already conducted a series of studies and is now advancing with a dose-response trial to pinpoint optimal dosages. While initial research suggests that as little as 22mg of sarmentosin is effective, upcoming studies will assess doses ranging from 2.5mg to 100mg, expected to conclude within a year. This research builds on A̅repa’s five double-blind, placebo-controlled human trials, aiming to establish sarmentosin’s effects further and evaluate its safety profile in healthy populations.
Market Trends
Trend 1: Increasing Demand for Natural Cognitive and Mood EnhancersAs consumer interest grows in natural alternatives to pharmaceuticals, sarmentosin’s potential as a plant-based MAO inhibitor offers a timely solution. Commonly found in pharmaceuticals for conditions like anxiety, depression, and Parkinson’s disease, MAO inhibitors are in high demand, but natural options are scarce. With A̅repa’s proprietary extraction technique, Neuroberry blackcurrants yield higher concentrations of sarmentosin, positioning the company as a leader in natural, cognition-enhancing solutions.
This trend towards plant-based mental wellness products is poised to reshape the supplement industry, particularly as A̅repa plans to launch in the US via e-commerce in 2024. The brand’s entry into a global market is a strategic move to meet rising consumer demand for functional, mental health-focused products, leveraging sarmentosin’s unique properties to differentiate itself.
Trend 2: Expansion of Ingredient Supply and Extraction InnovationAs A̅repa explores scaling sarmentosin extraction, it also seeks partnerships with ingredient firms, aiming to supply the molecule beyond its own product line. The potential for commercialising this ingredient hinges on efficient extraction, and A̅repa is investing in proprietary IP to ensure high-yield production. By situating its manufacturing in Canterbury, where its blackcurrants are cultivated, A̅repa can maintain control over quality and supply, paving the way to supply ingredient firms with consistent, high-potency sarmentosin for broader industry applications.
Strategic Action
1. Expand US Market Presence with Neuroberry-Based ProductsA̅repa’s entry into the US market capitalises on surging demand for natural cognitive enhancers. Key steps include:
E-Commerce Strategy: Introduce sarmentosin-based powder supplements through online platforms, creating brand recognition among US consumers interested in mental wellness.
Regulatory Preparations for Medical Foods: Develop a pathway for future medical food applications as sarmentosin gains regulatory clearance, enabling A̅repa to broaden its portfolio with therapeutic options.
Consumer Education: Build awareness around sarmentosin’s unique benefits, positioning it as a natural alternative to conventional mental wellness products and differentiating it in a crowded market.
2. Strengthen Ingredient Supply Chain with Proprietary Extraction TechniquesScaling production to supply ingredient firms marks a strategic move toward becoming a leader in sarmentosin-based solutions. To achieve this, A̅repa should:
Develop High-Yield Extraction: Continue refining proprietary IP for extracting sarmentosin efficiently, enhancing its potency and scalability.
Establish Local Manufacturing: Base production in Canterbury to ensure control over raw materials and reduce logistical costs, leveraging the high concentration of sarmentosin in New Zealand blackcurrants.
Forge Industry Partnerships: Collaborate with ingredient suppliers to incorporate sarmentosin into a wider range of products, from dietary supplements to functional foods, amplifying its market reach.
This approach positions A̅repa as both a product and ingredient supplier, providing flexibility to grow its revenue streams while securing sarmentosin’s place in the global wellness industry.
With its pioneering research and market entry plans, A̅repa’s focus on sarmentosin exemplifies the potential of nature-derived compounds to meet growing demands for mental wellness solutions. As sarmentosin progresses through research and regulatory stages, A̅repa’s strategy promises to unlock significant economic and health benefits, positioning New Zealand blackcurrants as a valuable source of cognitive support in global markets.
Comments